<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Epigenetic modulation of gene expression plays an important role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Furthermore, <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors may induce the reexpression or repression of genes critical for <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to evaluate the toxicity, pharmacokinetic profile, and selected pharmacodynamic properties of the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor <z:chebi fb="0" ids="23643">depsipeptide</z:chebi> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: <z:chebi fb="0" ids="23643">Depsipeptide</z:chebi> was administered to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients at a (<z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e>) phase I dose of 18 mg/m(2) i.v. on days 1 and 5 every 3 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicities and clinical activity were monitored and pharmacokinetic and pharmacodynamic studies were done </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Twelve patients (nine with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, three with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received one to five cycles of <z:chebi fb="0" ids="23643">depsipeptide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The most common grade 3/4 toxicities were febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (five patients), <z:hpo ids='HP_0001875'>neutropenia</z:hpo>/<z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (nine patients), <z:hpo ids='HP_0002018'>nausea</z:hpo> (nine patients), and asymptomatic <z:hpo ids='HP_0002148'>hypophosphatemia</z:hpo> (three patients) </plain></SENT>
<SENT sid="7" pm="."><plain>No clinically significant cardiac toxicity was observed </plain></SENT>
<SENT sid="8" pm="."><plain>The best response of 11 assessed patients was one complete remission in a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, stable disease in six patients, and progression of disease in four patients </plain></SENT>
<SENT sid="9" pm="."><plain>Exploratory laboratory studies showed modest but rapid increases in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and changes in myeloid maturation marker expression </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> H3 and H4 acetylation levels were evaluated in five patients; no consistent changes were observed </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="23643">Depsipeptide</z:chebi> therapy can be administered with acceptable short-term toxicity </plain></SENT>
<SENT sid="12" pm="."><plain>However, gastrointestinal symptoms and <z:mp ids='MP_0002899'>fatigue</z:mp> seem to be treatment-limiting after multiple cycles </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="23643">Depsipeptide</z:chebi> monotherapy has limited clinical activity in unselected <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients </plain></SENT>
</text></document>